Surgery Partners, Inc. (NASDAQ: SGRY) is a healthcare services company that operates surgical facilities across the United States. The company focuses on providing high-quality, cost-effective solutions for surgical procedures. It competes with other healthcare service providers in the industry, striving to expand its network and improve its service offerings.
On March 4, 2026, Jefferies maintained a "Buy" rating for SGRY, with a "hold" action, when the stock was priced at $14.40. This decision comes amid an ongoing investigation by Johnson Fistel, PLLP into potential claims on behalf of SGRY investors. The investigation centers on the company's executive officers and the possibility of recovering investor losses under federal securities laws.
The investigation follows SGRY's financial disclosure on March 2, 2026, where the company reported a full-year 2025 revenue of approximately $3.3 billion and an Adjusted EBITDA of $526.2 million. Despite exceeding revenue expectations, the company's profitability fell short, leading to a 14.1% decline in share price after the Q4 2025 results. This decline has prompted investors who suffered losses to consider joining the investigation.
SGRY has been expanding its surgical facilities, resulting in increased revenue per case. However, asset sales have led to a decrease in total case volume, impacting short-term results. Despite mixed profitability, SGRY trades at attractive EV/EBITDA and operating cash flow multiples compared to its peers, supporting Jefferies' soft 'buy' upgrade.
Currently, SGRY's stock is priced at $14.28, reflecting a 2.59% increase or $0.36. The stock's trading range for the day was between $13.74 and $14.65, with a market capitalization of approximately $1.85 billion. Over the past year, SGRY's stock has seen a high of $24.64 and a low of $12.25, with a trading volume of around 1.74 million shares.
